iRhythm Holdings, Inc

iRhythm Holdings, Inc(IRTC)股票分析

$121.270

+1.649 (+1.36%)收盘时

Loading chart…
最高
122.500
开盘
119.350
成交量加权均价
120.48
成交量
456.76K
市值
3.25B
最低
117.665
成交额
55.03M
企业价值/息税折旧摊销前利润(TTM)
40.52

iRhythm Holdings, Inc. is a digital health care company that creates solutions that detect, predict, and prevent disease. Combining its Zio wearable biosensors and cloud-based data analytics with proprietary algorithms, the Company distills data from millions of heartbeats into clinically actionable information. Each iRhythm ACM System combines a wire-free, patch-based, 14-day wearable biosensor (FDA-cleared, CE-marked and/or Japan PMDA-approved, as applicable) that continuously records ECG data with a proprietary, cloud-based data analytic software (FDA-cleared, CE-marked, and Japan PMDA-approved) to help physicians monitor patients and diagnose arrhythmias. The Company's products include the Zio monitor (long-term continuous monitoring) and Zio AT (mobile cardiac telemetry (MCT) monitoring). Its VitalConnect platform offers differentiated features such as up to 30-day patient monitoring, four-in-one functionality, flexible service models and live look-in.

AI 分析 of iRhythm Holdings, Inc (IRTC)

买入

iRhythm Technologies Inc (IRTC) is a good buy right now, trading at $121.27 with a significant upside potential. The company has shown a 24% annual revenue growth over the last two years and a gross margin of 72.80% in Q2 2026, indicating strong operational efficiency. However, a key risk is the high forward P/E ratio of 90.91, which suggests that the stock is priced for high growth, and any failure to meet growth expectations could lead to a decline in share price.

分析师评级(4)

上行空间 +83.06%
买入
3 买入
1 持有
0 卖出
当前: 121.27
最低
205.00
平均
222.00
最高
244.00

Wells Fargo

2026-10-06

目标价

$150

增持

Truist

2026-08-10

目标价

$168

买入

Canaccord

2026-08-07

目标价

$196

买入

Baird

2026-08-07

目标价

$165

跑赢大盘

Stephens

2026-07-22

目标价

$160

增持

估值指标

iRhythm Holdings, Inc(IRTC)当前预期市盈率为 90.91,5 年平均预期市盈率为 -9.91。

预期市盈率

合理
5 年均值 P/E
-9.91
当前P/E
90.91
高估
218.95
低估
-238.76

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
186.15
当前EV/EBITDA
40.52
高估
1089.01
低估
-716.71

预期市销率

低估
5 年均值 P/S
6.08
当前P/S
3.79
高估
8.00
低估
4.16

Alphio AI 对 IRTC 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%IRTC

$186.19

情景价格

基

基准

基准 · 50%IRTC

$184.84

情景价格

悲

悲观

悲观 · 25%IRTC

$178.24

情景价格

持有 IRTC 的大户

B

Braidwell LP

+ 持有IRTC

+24.47%

3个月收益率

S

Stephens Investment Management Group, LLC

+ 持有IRTC

-3.39%

3个月收益率

R

RTW Investments, LP

+ 持有IRTC

-9.13%

3个月收益率

R

Rock Springs Capital Management LP

+ 持有IRTC

-11.57%

3个月收益率

事件时间线

2026-10-02 (ET)

17:00:00

iRhythm Updates on Cybersecurity Incident Notification

2026-08-06 (ET)

16:30:00

iRhythm Acquires Vital Connect for $287.5 Million

16:30:00

iRhythm Reports Q2 Revenue of $224.17M, Exceeds Expectations

16:30:00

iRhythm Expects 2026 Revenue of $880M to $890M

资讯

IRTC 常见问题 —— 由 Alphio AI 解答

iRhythm Holdings, Inc. is a digital health care company that creates solutions that detect, predict, and prevent disease. Combining its Zio wearable biosensors and cloud-based data analytics with proprietary algorithms, the Company distills data from millions of heartbeats into clinically actionable information. Each iRhythm ACM System combines a wire-free, patch-based, 14-day wearable biosensor (FDA-cleared, CE-marked and/or Japan PMDA-approved, as applicable) that continuously records ECG data with a proprietary, cloud-based data analytic software (FDA-cleared, CE-marked, and Japan PMDA-approved) to help physicians monitor patients and diagnose arrhythmias. The Company's products include the Zio monitor (long-term continuous monitoring) and Zio AT (mobile cardiac telemetry (MCT) monitoring). Its VitalConnect platform offers differentiated features such as up to 30-day patient monitoring, four-in-one functionality, flexible service models and live look-in. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

iRhythm Technologies Inc (IRTC) is a good buy right now, trading at $121.27 with a significant upside potential. The company has shown a 24% annual revenue growth over the last two years and a gross margin of 72.80% in Q2 2026, indicating strong operational efficiency. However, a key risk is the high forward P/E ratio of 90.91, which suggests that the stock is priced for high growth, and any failure to meet growth expectations could lead to a decline in share price.

4 analysts cover IRTC: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 222.00.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易